Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

54.41 +0.11 (+0.20%)
Streaming Delayed Price Updated: 10:22 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 Next >
Medical Devices & Supplies - Specialty Stocks Q4 Teardown: Integer Holdings (NYSE:ITGR) Vs The Rest
Let’s dig into the relative performance of Integer Holdings (NYSE:ITGR) and its peers as we unravel the now-completed Q4 medical devices & supplies - specialty earnings season. 
Via StockStory
Medical Devices & Supplies - Specialty Stocks Q3 Recap: Benchmarking STAAR Surgical (NASDAQ:STAA)
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including STAAR Surgical... 
Via StockStory
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers. 
Via StockStory
How Do Investors Really Feel About Haemonetics?
 
Via Benzinga
(HAE) - Analyzing Haemonetics's Short Interest
 
Via Benzinga
Haemonetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
 
Via Benzinga
Earnings Scheduled For February 6, 2025
 
Via Benzinga
Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and... 
Via StockStory
3 Reasons to Avoid HAE and 1 Stock to Buy Instead
Haemonetics has gotten torched over the last six months - since October 2024, its stock price has dropped 20.1% to $63.39 per share. This was partly due to its softer quarterly results and might have... 
Via StockStory
Topics Supply Chain
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
How Is The Market Feeling About Haemonetics?
 
Via Benzinga
The Latest Analyst Ratings For Haemonetics
 
Via Benzinga
Deep Dive Into Haemonetics Stock: Analyst Perspectives (7 Ratings)
 
Via Benzinga
NYSE:HAE is not too expensive for the growth it is showing.
While growth is established for NYSE:HAE, the stock's valuation remains reasonable. 
Via Chartmill
Demystifying Haemonetics: Insights From 5 Analyst Reviews
 
Via Benzinga
HAEMONETICS CORP/MASS (NYSE:HAE) is probably undervalued for the fundamentals it is displaying.
HAEMONETICS CORP/MASS has caught the attention as a great value stock. NYSE:HAE excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill
Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers. 
Via StockStory
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Pack
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQ:STAA) and the best... 
Via StockStory
Despite its growth, NYSE:HAE remains within the realm of affordability.
HAEMONETICS CORP/MASS (NYSE:HAE), a growth stock which is not overvalued. 
Via Chartmill
What Analysts Are Saying About Haemonetics Stock
 
Via Benzinga
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect. 
Via StockStory
Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know. 
Via StockStory
For those who appreciate value investing, NYSE:HAE is a compelling option with its solid fundamentals.
HAEMONETICS CORP/MASS is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:HAE showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
Haemonetics (NYSE:HAE) Misses Q4 Revenue Estimates
Blood products company Haemonetics (NYSE:HAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per share was... 
Via StockStory
Earnings To Watch: Haemonetics (HAE) Reports Q4 Results Tomorrow
Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results tomorrow before the bell. Here’s what to expect. 
Via StockStory
While growth is established for NYSE:HAE, the stock's valuation remains reasonable.
For those who appreciate growth without the sticker shock, HAEMONETICS CORP/MASS (NYSE:HAE) is worth considering. 
Via Chartmill
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
In the world of growth stocks, NYSE:HAE shines as a value proposition. 
Via Chartmill
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
NYSE:HAE stands out as a growth opportunity that won't break the bank.
Investors should take note ofHAEMONETICS CORP/MASS (NYSE:HAE), a growth stock that remains attractively priced. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.